

Interstitial lung diseases

Restrictive lung diseases

Lung fibrosis

Creative Commons



Unlock your
creative potential!


”small” lungs

Asbestosis



Extensive fibrosis with emphysematous changes and great pleural thickening: visceral, parietal, and diaphragmatic. Lower lobe predominantly involved

Restriktive lung function




Also seen
without
problems in
the lung
parenchyma

The ribs of large curve; the lungs large and roomy; the liver, stomach and bowels in their normal position; all with abundant room.

The ribs bent almost to angles; the lungs contracted; the liver, stomach and intestines forced down into the pelvis, crowding the womb seriously.

Nature Versus Corsets Illustrated.



In principle there
is a "acute"
restriktive
disorder

Pleuraexsudate,
pneumonia
Atelektasis etc..

However. Normally in lungfibrosis

Disease localized in the paremkyma


What is lost is forever lost

...if treatment is not started in time...


Symptoms

- **Slowly progression**
 - But attracts is prevalent
- **Breathlessness**
 - At first at activity
 - Later all the time
- **cough**
 - Non- productive


- **Signs**
 - cyanosis
 - Low saturation
- low lung function
- Dromstikfingers
- Velcro sound at stethoscopy




As proposed by the project sponsor.



As specified in the project request.




As designed by the senior analyst.




As produced by the programmers.



As installed at the user's site.



What the user wanted.





D'oh!

However the initial most often mistake diagnosis that misinterpreted as lung fibrosis is ???


COPD !!!!

Why??






COPD
FVC is falsely
decreased




Alveolar deflation in the normal state

Cycle of deflation and inflation



Alveolar deflation in COPD

Cycle of deflation and inflation



“Air trapping”

“solved” by Slow vital capacity

$FVC < SVC$

Eller TLC

Odense Universitetshospital

Lungemedicinsk amb.: Lungefunktionsundersøgelse

17-12-2008

ID: 060955-1461
Name: Vadsø-Jensen, Knud Erik
Age: 53 (06-09-1955)
Gender: Male
Height: 184 cm.
Referred by:


Alias ID:
Exam Date: 17-12-2008 09:16
Origin: Caucasian **Factor:** 100
Weight: 57.0 kg. **Smoker:** 0
Occupation:

	VC	FEV1	FVC	PEF	VAR	Quality
Base		0.57	1.78	157	-14 %	Good Blow
Base		0.61	2.12	168	+0 %	Good Blow
Base		0.57	1.79	169	-14 %	Good Blow
+ Base		0.61	2.12	169	+0 %	

ATS/ERS Criteria (2005): Tests do not meet repeatability standards for FVC.

Variation is based on FEV1 + FVC

Index	Base	%Pred	Post 1	%Pred	Change	[Min	Pred	Max]	Units			
VC						0	2	4	6	8	10	12
FEV1	0.61	16				3.05	3.89	4.72	Time (s)	l		
FVC	2.12	43				3.88	4.88	5.88		l		
FEV1/FVC										%		
FEV1/FVC	29					66	78	89		%		
FET	8.70									s		



One clue is that the pt is obstructive
 Then wonder !!

SaO2 92
 puls 90-120

Udvidet Lungefunktionsundersøgelse

identifikation: 060955-1461 Fornavn: Knud Erik Efternavn: Vadsø-Jensen
fødselsdato: 06-09-1955 Alder: 53 Years Køn: male
højde: 184,0 cm Vægt: 60,0 kg Referencer: Standard

Spirometri:

		Test 1	% af forv.	Test 2	% af forv.	LL Forventet	UL	
Dato		05-01-09						
VC MAX	[L]	2.30	45.1 %			4.17	5.09	6.01
FVC	[L]	1.77	36.3 %			3.88	4.88	5.88
FEV 1	[L]	0.80	20.5 %			3.05	3.88	4.72
FEV 1 % FVC	[%]	44.98				65.91	77.67	89.43
FEV 1 % VC MAX	[%]	34.73	44.7 %			7.18	9.17	11.15
PEF	[L/s]	3.11	34.0 %					

TLC is normal

Kropspletysmografi:

		Test 1	% af forv.	Test 2	% af forv.	LL Forventet	UL	
TLC	[L]	8.78	115.1 %			6.47	7.62	8.77
RV	[L]	6.26	266.9 %			1.67	2.35	3.02

Diffusionsbestemmelse:

		Test 1	% af forv.	Test 2	% af forv.	LL Forventet	UL	
TLCO SB	[mmol/min/kPa]	1.12	10.3 %			8.60	10.91	13.23
TLCOc SB	[mmol/min/kPa]	1.14	10.5 %			8.60	10.91	13.23
VA	[L]	3.83	51.3 %			7.47	7.47	7.47
TLCO/VA	[mmol/min/kPa/L]	0.29	20.5 %			1.43	1.43	1.43
TLCOc/VA	[mmol/min/kPa/L]	0.30	20.8 %			1.43	1.43	1.43
Hb	[mmol/L]	8.70						

Myths !


- Smoking does **NOT** normally cause lung fibrosis
- However nothing without exceptions
Very rare lung diseases
- Smoking gives lungfibrosis.....????!!!



**The More I Think
The More Confused I Get**

Smoking-Related Interstitial Lung Disease


- ◆ Respiratory bronchiolitis
ILD (RBILD)
- ◆ Desquamative interstitial pneumonia (DIP)
- ◆ Pulmonary Langerhans' cell histiocytosis



Pigmented macrophages and inflammatory edema in the walls of the terminal and respiratory bronchioles

SIN







Back on Track


FØLG DIN ORDR



...interesting

TRACK & TRACE


Causes: Restrictive lung diseases




1. Changes in the lung parenchyma

=Lung fibrosis


2. Diseases in the pleura, chest wall, muscles and nerves



What happens in lung fibrosis ??




Scar tissue (fibrosis) in the lungs





NORMAL LUNG






Lung fibrosis decreased ability of oxygen uptake



Findings

- Decrease in saturation under activity
 - Later also at rest
- A-gas shows hypoxia not hypercapnia
 - Only in the Terminal fase is hypercapnia seen.
- So no problem giving oxygen (in contrast to COPD)
 - No tendency to develop hypercapnia


What do we have to measure in patients with lung fibrosis??




Fitted to a patient's jaws, the "gnathograph" registers the arrangement of teeth and direction of bite

WITH the aid of the "gnathograph," an instrument as mouth-filling as its name, a dentist's patients may now be assured of a perfect fit for artificial teeth. Fitted to the jaws as shown above, the new device registers the arrangement of the teeth and the direction of the "bite," to guide the dentist in straightening teeth or fitting inlays, crowns, bridges, and plates. Its inventor, Dr. Beverly B. McCollum of Los Angeles, Calif., demonstrates in the picture at the right how the instrument is then mounted for use in tooling a plate to just the right shape to give the most comfortable fit in the mouth.

Device Takes Measure of the Teeth



The device then serves as a guide in making plates



How To Measure



There is a slight difference in diagnosing and monitoring the disease

- Lung function
 - Forced volumen
 - TLC, RV and DLCO
- Anatomic changes
 - Bronkoscopy
 - HRCT scan
 - X-RTG Thorax
 - Ekko/hjertekat
 - Lungebiopsy
 - Dexa scanning
- Serological changes
 - Blood tests
- Activity
 - 6 min walking test






Always initially do TLC;RV and DLCO




UDVIDET LUNGEFUNKTIONSUNDERSØGELSE

Identification: 120844-
 First Name: Boris Telling
 Last Name: Sørensen
 Height: 174,0 cm
 Rel. Weight: 92 %
 Operator:
 Physician: --
 Last Test: 1

	Pred	Act1	Act2	Act3 (A1/P)	% (Best/Pred)
Date	07-07-2006				
ATS-ok	0.00				
FEV 1	3.22	2.08			64.6
FVC	4.10	2.24			54.8
FEV1%F	92.71				
FIV1	1.72				
MIF	0.68				
MEF	0.44				
PIF	2.47				
AIN					
TLC	6.82	3.41			50.0
RV	2.39	1.09			45.6
RV%TLC	37.75	31.97			84.7
Hb	15.40				
TLCoc	9.28	2.97			32.0
KCOc	1.36	0.98			72.4



TLC: How big a the lungs ?



TLCO: How "good" are the lungs to oxygen optake ?

6-min Walking test

- How far?
- Desaturation?
- Symptoms severe ?
- The test accesses the physical ability?
- Degree of severeness
- Disease development
- Guidance to when transplantation should be considered

6 MINUTTERS GANGTEST

120844-1627 CD L
Sørensen, Boris Telling
Jasminparken 22
6760 Ribe

Dato 7/12-07 Henvisende læge HDM

Illtilskud 0 Ganghjælpemiddel ✓

TID	DISTANCE	SATURATION
0 min.	0 m.	91%
0,37	50 m.	87%
1,14	100 m.	85%
1,53	150 m.	81%
2,30	200 m.	79%
3,07	250 m.	79%
3,44	300 m.	79%
4,19	350 m.	78%
4,53	400 m.	79%
5,26	450 m.	78%
6,06	500 m.	78%
	550 m.	
	600 m.	
	650 m.	
	700 m.	
	750 m.	
	800 m.	

Let
↑ tempo

Borgs Desaturation (0-10)


FØR	0
EFTER	5



Mette Anbjør


HRCT- scan

- Changes
 - distribution
 - Pattern
 - development
 - Effect of treatment
 - Changes in disease
- } Which disease ?
Who bad ?
Differential diagnosis ?
Further work-up ?



Nielsen,Erik
2705472125

C: 16384.0, B: 16384.0
VE, LIGGE KL. 13:55






21-03-2009, 14:24:57

Odense Universitetshospital


A1

CT versus HRCT



Always HRCT !!!



HRCT normal lung



HRCT in a patient with lungfibrosis (UIP)




Bloodtests

- Diagnosis
- Prognosis



"Off hand, I'd say you're suffering from an arrow through your head, but just to play it safe, I'm ordering a bunch of tests."

Bloodtests




- Common bloodtests.....
- Extra Interstitial blood tests:
 - ACE: Sarcoidose
 - ANA: Relaterede to ex - (SLE,RA)
 - ANCA: Wegeners granulomatosis
 - Anti-CCP Reumatoid arthritis
 - IgM-RF Reumatoid arthritis
 - GBA Goodpasteurs disease
 - SLC-70 Sclerodermi
- Arterial-gas



Collagen-Vascular Disorders


UIP due to underlying collagen vascular disease is associated with a much better prognosis than idiopathic UIP (IPF)

- usual treatment consists of standard immunosuppressive regimens.



Bronchoscopy

WEDGE RESECTION



Open lung biopsy

is


Trachea (windpipe)

Collar bone

Right lung

Left bronchus

Left lung



And then!

Think!


Dignosis !


Treatment!'

Remember ONLY
For lungspecialist!!!



classification





Survival is dependent on the diagnosis

usual interstitial pneumonia (UIP), fibrotic nonspecific interstitial pneumonia (NSIP), and desquamative interstitial pneumonia (DIP)/respiratory bronchiolitis-associated interstitial lung disease (RBILD)/cellular NSIP

Restrictive diseases

Intrinsic lung diseases

- Interstitial lung diseases
 - » Arthritis related (SLE, RA, scleroderma)
 - » “Ideopathic” (ex UIP)
 - “smoke related” (ex Histeocytosis X)
- Asbestosis/silicosis
- Allergic (allergic alveolitis)
- Pleura (debris-exsudat)
- Medicine (nitrofurantoin, amiodarone, bleomycin).
- Pneumonia
- radiation



Extrinsic diseases (extra-parenchymale diseases)

- Non-neuromuskular
 - Deformities
 - Heart disease
 - ARDS
 - Neuromuscular
 - Poliomyelitis, Guillain-Barre syndrome, ALS, myasthenia gravis, muscular dystrophies
- Inflammation and/or scarring of lung tissue
- reduced space or muscular power
- Fill airspaces exudat/debris (pneumonitis)

Treatment

- Immunosupresiva
 - Prednisolon
 - One time
 - Continuos
 - Others
 - Azatioprime; metrotrexate, cyclosporine many others
- Anti-inflammatory
 - acetylcysteine
- Removal of cause
 - Allergic alveolitis
 - Langerhans histeocytosis X;REBILD



a C.F.'s guide to the transplant experience

TABLE 1. DISEASE-SPECIFIC GUIDELINES FOR REFERRAL FOR LUNG TRANSPLANTATION.*

Chronic obstructive pulmonary disease

FEV₁ <25 percent of predicted value after bronchodilator therapy
Clinically significant hypoxemia, hypercapnia, or pulmonary hypertension;
rapid decline in lung function; or frequent severe exacerbations

Idiopathic pulmonary fibrosis

Symptomatic disease unresponsive to medical therapy
Vital capacity <60 to 70 percent of predicted value
Evidence of resting or exercise-induced hypoxemia

Cystic fibrosis

FEV₁ ≤30 percent of predicted value
FEV₁ >30 percent with rapidly declining lung function, frequent severe ex-
acerbations, or progressive weight loss
Female sex and age of less than 18 years with FEV₁ >30 percent†

Primary pulmonary hypertension

NYHA functional class III or IV
Mean pulmonary-artery pressure >55 mm Hg
Mean right atrial pressure >15 mm Hg
Cardiac index <2 liters/min/m²
Failure of medical therapy, especially intravenous epoprostenol, to improve
NYHA functional class or hemodynamic indexes


Eisenmenger's syndrome

NYHA functional class III or IV despite optimal medical management


- transplantation is dependent on the disease

Worldwide Lung Transplantation Numbers

Lung transplants performed worldwide, by year



Primary diagnosis, 01/1995 - 06/2003






Figure 1. Lung Transplantation in the United States, 1988 to 1997.






Figure 2. Actuarial Survival after Lung Transplantation.

Comparative Transplantation Survival Rates



*Kidney, liver, and heart data extrapolated from OPTN Annual Report, 2003.

Causes of Death Following Lung Transplantation



Status for Lung transplantation

- **Survival —50% died after 5 years**
- **Bronchiolitis obliterans main reason for a bad survival rate**
- **Main aim to treat and prevent bronchiolitis obliterans**

More time???



NO MA'AM